scholarly journals Overexpression of Indoleamine 2,3-Dioxygenase in Human Endometrial Carcinoma Cells Induces Rapid Tumor Growth in a Mouse Xenograft Model

2008 ◽  
Vol 14 (22) ◽  
pp. 7251-7259 ◽  
Author(s):  
Norio Yoshida ◽  
Kazuhiko Ino ◽  
Yoshiyuki Ishida ◽  
Hiroaki Kajiyama ◽  
Eiko Yamamoto ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Endometrial Carcinoma ◽  
Xenograft Model ◽  
Carcinoma Cells ◽  
Mouse Xenograft ◽  
Indoleamine 2,3 Dioxygenase ◽  
Mouse Xenograft Model

scholarly journals Prostate Tumor Growth and Recurrence Can Be Modulated by the ω-6:ω-3 Ratio in Diet: Athymic Mouse Xenograft Model Simulating Radical Prostatectomy

Neoplasia ◽  
2006 ◽  
Vol 8 (2) ◽  
pp. 112-124 ◽  
Author(s):  
Uddhav P. Kelavkar ◽  
Justin Hutzley ◽  
Rajiv Dhir ◽  
Paul Kim ◽  
Kenneth G.D. Allen ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
Tumor Growth ◽  
Xenograft Model ◽  
Prostate Tumor ◽  
Athymic Mouse ◽  
Mouse Xenograft ◽  
Mouse Xenograft Model

Cyclopamine Reduces the Growth of Endometrial Carcinoma and Hedgehog Pathway Proteins in a Xenograft Mouse Model

2021 ◽  
Vol 11 (3) ◽  
pp. 420-425
Author(s):  
Zhengxing He ◽  
Jing Zeng ◽  
Yalan Xu
Keyword(s):  
Tumor Growth ◽  
Receptor Antagonist ◽  
Endometrial Carcinoma ◽  
Mrna Expression ◽  
Xenograft Model ◽  
Female Reproductive Tract ◽  
Tumor Growth Rate ◽  
Inhibition Rate ◽  
Transplanted Tumors ◽  
Mouse Xenograft Model

Endometrial carcinoma is a frequently occurring malignancy of the female reproductive tract. Previous investigations have implicated the Hedgehog signaling pathway, including the smoothened (Smo) receptor, in tumor progression. Here, we established a nude mouse xenograft model of endometrial cancer to investigate the effect of the Smo receptor antagonist cyclopamine on the growth of endometrial carcinoma. Mice were randomly sorted into two groups receiving 0.2 mL/mouse every other day of either cyclopamine (20 mg/mL) or solvent (control). The growth of the mice was observed for 18 days. Then, mice were euthanized, tumors were removed and weighed, and tumor volume inhibition rate (VIR) and weight inhibition rate (WIR) were calculated. Smo, Gli1, and Gli2 mRNA expression was measured in tumor tissues by RT-PCR, and Vascular endothelial growth factor (VEGF) and CD31 were detected by immunohistochemistry. We found that cyclopamine treatment reduced the tumor growth rate and significantly reduced the volumes and weights of the transplanted tumors compared with those of the controls. Furthermore, the transplanted tumors of cyclopamine-treated mice possessed lower expression levels of Smo, Gli1, and Gli2, and displayed a lower positive expression of VEGF and CD31. Thus, the Smo receptor antagonist cyclopamine inhibited transplanted tumor growth in nude mice with endometrial carcinoma, which is likely connected with cyclopamine downregulation of Smo, Gli1, and Gli2 mRNA expression that promote angiogenesis.

scholarly journals Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth

Blood ◽  
2017 ◽  
Vol 129 (17) ◽  
pp. 2420-2428 ◽  
Author(s):  
Bojan Bujisic ◽  
Aude De Gassart ◽  
Rémy Tallant ◽  
Olivier Demaria ◽  
Léa Zaffalon ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Xenograft Model ◽  
Mouse Xenograft ◽  
Mouse Xenograft Model ◽  
Key Points

Key PointsGCB DLBCLs are characterized by a defective IRE1-XBP1 pathway. XBP1 expression reduces GCB DLBCL tumor growth in a mouse xenograft model.

scholarly journals Celecoxib inhibits meningioma tumor growth in a mouse xenograft model

Cancer ◽  
2007 ◽  
Vol 109 (3) ◽  
pp. 588-597 ◽  
Author(s):  
Brian T. Ragel ◽  
Randy L. Jensen ◽  
David L. Gillespie ◽  
Stephen M. Prescott ◽  
William T. Couldwell
Keyword(s):  
Tumor Growth ◽  
Xenograft Model ◽  
Mouse Xenograft ◽  
Mouse Xenograft Model

scholarly journals Novel LIMK2 inhibitor blocks Panc-1 tumor growth in a mouse xenograft model

Oncoscience ◽  
2014 ◽  
Vol 1 (1) ◽  
pp. 39-48 ◽  
Author(s):  
Roni Rak ◽  
Roni Haklai ◽  
Galit Elad-Tzfadia ◽  
Haim J. Wolfson ◽  
Shmuel Carmeli ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Xenograft Model ◽  
Mouse Xenograft ◽  
Mouse Xenograft Model

scholarly journals Distinct inhibitory efficiency of siRNAs and DNAzymes to β1 integrin subunit in blocking tumor growth.

2013 ◽  
Vol 60 (1) ◽  
Author(s):  
Magdalena Wiktorska ◽  
Izabela Sacewicz-Hofman ◽  
Olga Stasikowska-Kanicka ◽  
Marian Danilewicz ◽  
Jolanta Niewiarowska
Keyword(s):  
Tumor Growth ◽  
Xenograft Model ◽  
Tumor Formation ◽  
Integrin Subunit ◽  
Β1 Integrin ◽  
Mouse Xenograft ◽  
Mouse Xenograft Model ◽  
Intracellular Compartments

Receptors of the β1 integrin family are involved in many tumor-promoting activities. There are several approaches currently used to control integrin activity, and thus to potentially restrain tumor metastasis and angiogenesis. In this study, we compared inhibitory efficiencies of siRNA and DNAzymes against the β1 integrin subunit (DEβ1), in a mouse xenograft model. Both inhibitors were used under their most favorable conditions, in terms of concentrations, incubation time and lack of cytotoxic effects. Transfection of siRNAβ1 or DEβ1 remarkably inhibited the growth of both PC3 and HT29 colon cancer cells in vitro, and decreased their capability of initiating tumor formation in the mouse xenograft model. siRNAβ1 appeared to be slightly more efficient than DEβ1 when tested in vitro, however it was comparably less proficient in blocking the tumor growth in vivo. We conclude the DNAzyme, due to its greater resistance to degradation in extra- and intracellular compartments, to be a superior inhibitor of tumor growth in long lasting experiments in vivo when compared to siRNA, while the latter seems to be more efficient in blocking β1 expression during in vitro experiments using cell cultures.

Sign in / Sign up

Export Citation Format

Share Document